Document Detail

Humoral-targeted immunotherapies in multiple sclerosis.
MedLine Citation:
PMID:  23208729     Owner:  NLM     Status:  MEDLINE    
The continuous improvements of our understanding of the pathophysiological changes that occur in multiple sclerosis (MS) have translated into many novel therapeutic agents at different stages of development. These agents target more specifically the innate or the adaptive immune response. We will review agents available or under development that target the humoral pathways of the adaptive immune response. As such, humoral targeted immunotherapies that are being developed for MS are discussed herein: rituximab, ocrelizumab, and ofatumumab show promise as B-cell depleting agents. Other agents, such as atacicept were suspended during development in MS due to increased inflammatory activity versus the placebo. Although most agents were tested in relapsing-remitting forms of MS, rituximab and ocrelizumab have both been studied in progressive MS, whereas ocrelizumab only is currently moving forward in primary progressive MS trials. We provide an overview of agents available and under development that target the humoral response and include their mechanisms of action, safety profiles, and results of clinical trials.
Sabeen Lulu; Emmanuelle Waubant
Related Documents :
24219909 - Macrophages polarization and function with emphasis on the evolving roles of coordinate...
23251389 - Wogonin induced calreticulin/annexin a1 exposure dictates the immunogenicity of cancer ...
22951229 - Biostatic activity of piscine serum and mucus on myxozoan fish infective stages.
23072749 - Immunologic privilege in the central nervous system and the blood-brain barrier.
23927879 - Suppression of t-cell activation in vitro and in vivo by cordycepin from cordyceps m...
23915129 - Mitochondria-targeted antioxidant mitoq ameliorates experimental mouse colitis by suppr...
67339 - Depressed lymphocyte function after bereavement.
25447409 - Epithelial-mesenchymal transition and cancer stem cells, mediated by a long non-coding ...
19380879 - Bax activation by the bh3-only protein puma promotes cell dependence on antiapoptotic b...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics     Volume:  10     ISSN:  1878-7479     ISO Abbreviation:  Neurotherapeutics     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-29     Completed Date:  2013-07-29     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  101290381     Medline TA:  Neurotherapeutics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  34-43     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antibodies, Monoclonal, Murine-Derived / therapeutic use
B-Lymphocytes / drug effects,  immunology
Immunity, Humoral / drug effects*,  immunology
Immunosuppressive Agents / therapeutic use*
Immunotherapy / methods*
Multiple Sclerosis / immunology,  therapy*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Monoclonal, Murine-Derived; 0/Immunosuppressive Agents; 0/ocrelizumab; 0/ofatumumab; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Neuroimaging in mitochondrial disorders.
Next Document:  A molecular photovoltaic system based on Dawson type polyoxometalate and porphyrin formed by layer-b...